Stock·NASDAQ·Technology
Cognizant Technology Solutions Corp. (CTSH)
- Market cap
- $31.23B
- P/E
- 14.14
- Dividend yield
- 1.97%
- Street target
- $66.00median of 28 analysts
- 52-week range
- $37.08 $87.03
The short version
Where CTSH stands today, in four lines, and what CleaRank Financial AI makes of it.
CTSH at a glance
Cognizant Technology Solutions Corp. (CTSH): Buy, 71/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($60.38 and $59.77).
- Earnings CTSH beat estimates in 4 of its last 5 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $8.0M and bought $210K over the last 18 months.
- Valuation P/E of 14.1 against 35.1 for the Technology sector: a discount to peers (-60%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Cognizant Technology Solutions Corp. (CTSH) Buy, with a model score of 71/100.
The trend lifts the score most: the price is 10.47% above its 200-day average and 9.36% above its 50-day average, and the 50-day average is 1.01% above the 200-day. Revenue growth holds it back most: revenue grew 4.50%, 19.7 percentage points slower than the sector median. The 50-day average stands at $60.38 and the 200-day at $59.77. Over the past year the price rose 0.86%.
Only on CleaRank
Figures we compute ourselves from CTSH's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $66.03 is 9.4% above the 50-day simple moving average of $60.38.Price above its 200-day average ›
The price is 10.5% above the 200-day simple moving average of $59.77.50-day average above the 200-day ›
The 50-day average ($60.38) is 1.0% above the 200-day average ($59.77), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 58% of its 52-week range, between $37.08 and $87.03.
CTSH share price
Pick a period: each tab shows how far CTSH has moved over it, to the last close.
Today's trading
Where CTSH sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 14.14 is 59.7% below the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 1.44 is 81.1% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $2.2B on revenue of $21.6B, a net margin of 10.3%.Beat estimates in most recent reports ›
CTSH beat the EPS estimate in 4 of its last 5 reports.Pays a dividend ›
The trailing dividend yield is 1.97%, or $1.30 a share a year.
Key statistics
The headline figures for CTSH.
As of October 17, 2026, CTSH trades at $66.03, with a market value of $31.23B, a P/E ratio of 14.14 and a dividend yield of 1.97%.
What the numbers say
CleaRank Financial AI's reading of CTSH's valuation, growth and risks.
Cognizant Technology Solutions Corp. (CTSH) is priced at a trailing P/E of 14.14, which is 59.7% under the Technology sector median of 35.1. The peer comparison on this page gives it a verdict of a discount to peers. Its price-to-sales ratio of 1.44 is 81.1% under the sector median of 7.6.
Revenue growth lags the sector: the business grew revenue 4.50% in its latest year, while the sector median stands at 24.2%. Profit margins are healthier, with a net margin of 10.26%, an operating margin of 17.48%, and a return on equity of 14.92% that sits above the sector median of 13.4%. CTSH carries debt-to-equity of 0.14, and its trailing dividend yield is 1.97%, paying $1.30 a share each year.
CTSH's most recent quarterly report, released on July 29, 2026, came in below expectations: EPS of $1.37 a share compared with an estimate of $1.38, a miss of 0.72%. In the first session after the report, the share price dropped 3.70%.
The earnings record shows 4 beats in 5 reports; even so, 1 of those 4 beats was followed by a lower share price the next session. Earlier, the stock rose 4.17% after the February 5, 2025 report, a beat of 7.08%. The consensus EPS estimate stands at $5.76 for this fiscal year and $6.34 for next, growth of 9.0% for the current year.
CTSH typically moves about 2.83% on a given day. The price is 24.13% under its 52-week high of $87.03. Over the last 18 months, insiders sold $8.0M of stock and bought $210K. Insider sales are often planned ahead or made to cover tax on vesting shares, so they carry less weight than open-market purchases.
CTSH against the Technology sector
How CTSH compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: CTSH trades at a notable discount to sector peers (-60%), which may indicate undervaluation or specific company headwinds.
Return vs XLK: Since May 6, 2025, CTSH has lost 15.0% against a gain of 71.7% for XLK.
Performance against XLK
CTSH and the Technology sector fund over the same days.
Revenue and earnings
How much CTSH sells, and how much of it becomes profit.
Revenue growth: Revenue grew 7.0% in FY2025 to $21.1B, from $19.7B a year earlier.
Profit margin: The net margin was 10.6% in FY2025, down from 11.3% the year before.
Profitable: CTSH earned $2.2B in FY2025.
Earnings reality check
Did CTSH beat what analysts expected, and how did the stock react?
Earnings record: CTSH beat the analyst estimate in 4 of the last 5 quarters.
Market reaction: The stock fell in the first session after 1 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 29, 2026after close | $1.38 | $1.37 | -0.72% | -3.70% | -0.34% |
| Jul 30, 2025after close | $1.26 | $1.31 | +3.97% | -2.41% | -3.59% |
| Apr 30, 2025after close | $1.20 | $1.23 | +2.50% | +2.26% | +5.93% |
| Feb 5, 2025after close | $1.13 | $1.21 | +7.08% | +4.17% | +5.36% |
| Oct 30, 2024after close | $1.15 | $1.25 | +8.70% | +0.32% | +6.79% |
As of October 17, 2026, CTSH has beaten the analyst EPS estimate in 4 of its last 5 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 29, 2026, came in 0.72% below the estimate and the stock moved -3.70% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 67.6, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 67.6 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of CTSH
The score, the reasoning behind it, and what could move the price next.
CTSH is trending up. The stock sits at $66.03, which is 9.36% above its 50-day average of $60.38 and 10.47% above its 200-day average of $59.77. The 50-day average is also 1.01% above the 200-day, so the two averages point the same way. Over the past year, the price is 78.07% above the 52-week low of $37.08 and 24.13% below the high of $87.03.
The 14-day RSI of 67.6 is in the bullish zone, below the overbought line, and the MACD line is positive. The record is positive across every period shown: the price rose 47.49% over the past three months, rose 7.72% over the past six months and rose 0.86% over the past year.
Rating reaffirmed ›
Wedbush kept its Outperform rating on October 9, 2026.
Source: Analyst action, Wedbush, October 9, 2026
Earnings miss ›
The July 29, 2026 report missed the EPS estimate by 0.72%, and the share price fell 3.70% in the first session after it.
Source: Earnings report, July 29, 2026
- The two nearest levels to watch are the 52-week high at $87.03, above the price, and the 20-day EMA at $60.68, below it.
- A 14-day RSI of 67.6 lands in the bullish zone, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- The share price dropped 3.70% in the first session after the July 29, 2026 report. Even so, CTSH has beaten estimates in 4 of the last 5 reports.
CTSH's uptrend depends on the price holding above its 50-day average of $60.38 and its 200-day average of $59.77. A close below the 50-day average would be the first sign of weakness. If the price pulls back, the first level it would reach is the 20-day EMA at $60.68.
CTSH's next level overhead is its 52-week high of $87.03. The RSI sits in the bullish zone, which suggests momentum is still supporting the advance.
Technical indicators
Momentum and trend for CTSH, from its daily closes.
As of October 17, 2026, with CTSH at $66.03, its 14-day RSI is 67.6 (showing bullish momentum without being overbought), its 50-day simple moving average is $60.38 and its 200-day is $59.77.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CTSH moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, CTSH's 1-year correlation of daily returns is +0.32 with S&P 500 (SPY), +0.19 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and -0.04 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
0/3Most analysts rate it a buy ›
12 of 28 analysts rate it a buy or strong buy, 16 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $66.00 is 0.0% below the price.More buy ratings than three months ago ›
12 of 28 rate it a buy now, against 13 of 29 three months ago.
CTSH Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | Wedbush | Reiterates | Outperform |
| Oct 2, 2026 | Wedbush | Reiterates | Outperform |
| Sep 18, 2026 | Deutsche Bank | Maintains | Buy |
| Sep 18, 2026 | TD Cowen | Reiterates | Hold |
| Jul 30, 2026 | Citigroup | Maintains | Neutral |
| Jul 30, 2026 | Susquehanna | Maintains | Positive |
As of October 17, 2026, 28 Wall Street analysts cover CTSH: 12 rate it a buy or strong buy, 16 a hold and 0 a sell or strong sell. Their 12-month price targets range from $47.00 to $93.00, with a median of $66.00, 0.0% below the price of $66.03.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CTSH trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CTSH's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CTSH tends to move, against the market and on its own.
The long record
CTSH's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 2.83% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 53.8%, from February 2025 to June 2026; the price is still 23.4% below that peak.Most 1-year holds ended higher ›
57% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $15,119, against $42,055 in the S&P 500 (SPY).
CTSH Drawdowns & Recovery
As of October 17, 2026, CTSH's worst peak-to-trough fall over the last 10 years with dividends reinvested was -53.8% (February 2025 to June 2026); it is still 23.4% below that peak, and 57% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CTSH in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CTSH trailed the S&P 500 over this period: $15,119 against $42,055.
A $10,000 investment in CTSH in October 2016 would be worth about $15,119 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CTSH, and which have not.
Strongest month, November: an average of +5.34%, up in 7 of 10 years.
Weakest month, March: an average of -3.80%, up in 4 of 10 years.
This month, October: has averaged +0.06%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CTSH's strongest calendar month has been November (average +5.34%, up in 7 of 10 years) and its weakest March (average -3.80%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CTSH, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CTSH today could grow to about $15,725 by 2036 in the base case, with a 90th-percentile outcome near $52,588 and a 10th-percentile outcome around $4,702. The simulation models price only; at today's 1.97% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CTSH Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $79.14 for CTSH by 2030 in the base case, from $66.03 today (1.2x over 4 years). The 10th-percentile path ends near $36.88. These are outcomes of a Monte Carlo simulation run on CTSH's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $47.16 | $69.09 | $101 | |
| 2028 | $42.13 | $72.29 | $124 | |
| 2029 | $39.04 | $75.63 | $147 | |
| 2030 | $36.88 | $79.14 | $170 | |
| 2031 | $35.26 | $82.80 | $194 |
Method: a lognormal simulation of CTSH's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
CTSH insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $210K on the open market and sold $8.0M.
As of October 17, 2026, CTSH insiders reported 37 open-market sales worth $8.0M and 1 open-market purchase worth $210K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Alina Kerdman
Officer
|
Grant | 207 | - |
| Sep 15, 2026 | Balu Ganesh Ayyar
Officer
|
Grant | 849 | - |
| Sep 15, 2026 | Kathryn Diaz
Officer
|
Grant | 749 | - |
| Sep 15, 2026 | Surya Kumari Gummadi
Officer
|
Grant | 2.0K | - |
| Sep 15, 2026 | Alina Kerdman
Officer
|
Grant | 200 | - |
| Sep 15, 2026 | John Sunshin Kim
Officer
|
Grant | 1.6K | - |
| Sep 15, 2026 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 6.0K | - |
| Sep 14, 2026 | Alina Kerdman
Officer
|
Sell | 134 | $8.4K |
| Sep 2, 2026 | John Sunshin Kim
Officer
|
Sell | 2.5K | $158.4K |
| Sep 1, 2026 | Balu Ganesh Ayyar
Officer
|
Grant | 2.1K | - |
| Sep 1, 2026 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 6.4K | - |
| Sep 1, 2026 | Kathryn Diaz
Officer
|
Grant | 2.1K | - |
| Sep 1, 2026 | Surya Kumari Gummadi
Officer
|
Grant | 5.2K | - |
| Sep 1, 2026 | Alina Kerdman
Officer
|
Grant | 621 | - |
| Sep 1, 2026 | John Sunshin Kim
Officer
|
Grant | 4.4K | - |
| Sep 1, 2026 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 15.1K | - |
| Sep 1, 2026 | Rajesh Varrier
Officer
|
Grant | 544 | - |
| Aug 31, 2026 | Alina Kerdman
Officer
|
Sell | 144 | $9.1K |
| Aug 3, 2026 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Sell | 12.0K | $669.2K |
| Aug 3, 2026 | John Sunshin Kim
Officer
|
Sell | 2.5K | $142.6K |
| Jul 1, 2026 | Alina Kerdman
Officer
|
Sell | 137 | $5.5K |
| Jul 1, 2026 | Alina Kerdman
Officer
|
Grant | 207 | - |
| Jun 15, 2026 | Alina Kerdman
Officer
|
Sell | 133 | $6.9K |
| Jun 15, 2026 | Balu Ganesh Ayyar
Officer
|
Grant | 848 | - |
| Jun 15, 2026 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 2.5K | - |
| Jun 15, 2026 | Kathryn Diaz
Officer
|
Grant | 747 | - |
| Jun 15, 2026 | Surya Kumari Gummadi
Officer
|
Grant | 2.0K | - |
| Jun 15, 2026 | Alina Kerdman
Officer
|
Grant | 199 | - |
| Jun 15, 2026 | John Sunshin Kim
Officer
|
Grant | 1.6K | - |
| Jun 15, 2026 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 6.0K | - |
| Jun 15, 2026 | Rajesh Varrier
Officer
|
Grant | 1.3K | - |
| Jun 10, 2026 | Stephen J Rohleder
Director
|
Buy | 4.0K | $209.8K |
| Jun 3, 2026 | Zein M. Abdalla
Director
|
Grant | 2.9K | - |
| Jun 3, 2026 | Vinita Bali
Director
|
Grant | 2.9K | - |
| Jun 3, 2026 | Archana Deskus
Director
|
Grant | 2.9K | - |
| Jun 3, 2026 | Michael Patsalos-Fox
Director
|
Grant | 2.9K | - |
| Jun 3, 2026 | Abraham Schot
Director
|
Grant | 2.9K | - |
| Jun 3, 2026 | Karima Silvent
Director
|
Grant | 2.9K | - |
| Jun 3, 2026 | Joseph M Velli
Director
|
Grant | 2.9K | - |
| Jun 1, 2026 | Alina Kerdman
Officer
|
Sell | 146 | $8.2K |
| Jun 1, 2026 | Balu Ganesh Ayyar
Officer
|
Grant | 2.1K | - |
| Jun 1, 2026 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 6.4K | - |
| Jun 1, 2026 | Kathryn Diaz
Officer
|
Grant | 2.1K | - |
| Jun 1, 2026 | Surya Kumari Gummadi
Officer
|
Grant | 5.2K | - |
| Jun 1, 2026 | Alina Kerdman
Officer
|
Grant | 619 | - |
| Jun 1, 2026 | John Sunshin Kim
Officer
|
Grant | 4.4K | - |
| Jun 1, 2026 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 15.1K | - |
| Jun 1, 2026 | Rajesh Varrier
Officer
|
Grant | 542 | - |
| May 18, 2026 | Alina Kerdman
Officer
|
Sell | 154 | $7.4K |
| Apr 2, 2026 | Alina Kerdman
Officer
|
Sell | 194 | $11.9K |
| Apr 1, 2026 | Alina Kerdman
Officer
|
Grant | 207 | - |
| Mar 16, 2026 | Alina Kerdman
Officer
|
Sell | 131 | $8.0K |
| Mar 13, 2026 | Balu Ganesh Ayyar
Officer
|
Grant | 8.6K | - |
| Mar 13, 2026 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 31.3K | - |
| Mar 13, 2026 | Kathryn Diaz
Officer
|
Grant | 4.6K | - |
| Mar 13, 2026 | Surya Kumari Gummadi
Officer
|
Grant | 12.4K | - |
| Mar 13, 2026 | Alina Kerdman
Officer
|
Grant | 200 | - |
| Mar 13, 2026 | John Sunshin Kim
Officer
|
Grant | 12.6K | - |
| Mar 13, 2026 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 69.1K | - |
| Mar 13, 2026 | Rajesh Varrier
Officer
|
Grant | 5.5K | - |
| Mar 6, 2026 | Kathryn Diaz
Officer
|
Grant | 468 | - |
| Mar 4, 2026 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 2.2K | - |
| Mar 2, 2026 | Alina Kerdman
Officer
|
Sell | 151 | $9.5K |
| Feb 27, 2026 | Balu Ganesh Ayyar
Officer
|
Grant | 903 | - |
| Feb 27, 2026 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 2.0K | - |
| Feb 27, 2026 | Kathryn Diaz
Officer
|
Grant | 744 | - |
| Feb 27, 2026 | Surya Kumari Gummadi
Officer
|
Grant | 1.8K | - |
| Feb 27, 2026 | Alina Kerdman
Officer
|
Grant | 227 | - |
| Feb 27, 2026 | John Sunshin Kim
Officer
|
Grant | 2.2K | - |
| Feb 27, 2026 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 5.3K | - |
| Feb 17, 2026 | Alina Kerdman
Officer
|
Sell | 160 | $10.7K |
| Feb 13, 2026 | Balu Ganesh Ayyar
Officer
|
Grant | 1.1K | - |
| Feb 13, 2026 | Kathryn Diaz
Officer
|
Grant | 377 | - |
| Feb 13, 2026 | Surya Kumari Gummadi
Officer
|
Grant | 1.4K | - |
| Feb 13, 2026 | Alina Kerdman
Officer
|
Grant | 235 | - |
| Feb 13, 2026 | John Sunshin Kim
Officer
|
Grant | 2.1K | - |
| Feb 13, 2026 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 5.8K | - |
| Feb 2, 2026 | Surya Kumari Gummadi
Officer
|
Sell | 1.7K | $143.5K |
| Jan 7, 2026 | Michael Patsalos-Fox
Director
|
Sell | 2.0K | $168.5K |
| Jan 5, 2026 | Michael Patsalos-Fox
Director
|
Sell | 3.0K | $245.7K |
| Jan 2, 2026 | Surya Kumari Gummadi
Officer
|
Sell | 7.0K | $570.0K |
| Dec 31, 2025 | Alina Kerdman
Officer
|
Sell | 203 | $17.1K |
| Dec 31, 2025 | Alina Kerdman
Officer
|
Grant | 310 | - |
| Dec 29, 2025 | Michael Patsalos-Fox
Director
|
Sell | 3.0K | $255.5K |
| Dec 24, 2025 | Michael Patsalos-Fox
Director
|
Sell | 7.0K | $596.7K |
| Dec 19, 2025 | Ravi Kumar Singisetti
Chief Executive Officer
|
Sell | 3.0K | $250.9K |
| Dec 15, 2025 | Michael Patsalos-Fox
Director
|
Sell | 3.0K | $251.6K |
| Dec 15, 2025 | Alina Kerdman
Officer
|
Sell | 131 | $11.1K |
| Dec 15, 2025 | Balu Ganesh Ayyar
Officer
|
Grant | 848 | - |
| Dec 15, 2025 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 2.8K | - |
| Dec 15, 2025 | Kathryn Diaz
Officer
|
Grant | 773 | - |
| Dec 15, 2025 | Surya Kumari Gummadi
Officer
|
Grant | 2.3K | - |
| Dec 15, 2025 | Alina Kerdman
Officer
|
Grant | 199 | - |
| Dec 15, 2025 | John Sunshin Kim
Officer
|
Grant | 1.6K | - |
| Dec 15, 2025 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 6.0K | - |
| Dec 15, 2025 | Rajesh Varrier
Officer
|
Grant | 1.5K | - |
| Dec 12, 2025 | John Sunshin Kim
Officer
|
Sell | 5.0K | $418.4K |
| Dec 11, 2025 | Michael Patsalos-Fox
Director
|
Sell | 7.0K | $584.7K |
| Dec 5, 2025 | Kathryn Diaz
Officer
|
Grant | 468 | - |
| Dec 4, 2025 | Ravi Kumar Singisetti
Chief Executive Officer
|
Sell | 3.1K | $250.0K |
| Dec 4, 2025 | John Sunshin Kim
Officer
|
Sell | 2.5K | $200.0K |
| Dec 4, 2025 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 2.2K | - |
| Dec 1, 2025 | Surya Kumari Gummadi
Officer
|
Sell | 7.0K | $544.9K |
| Dec 1, 2025 | Alina Kerdman
Officer
|
Sell | 151 | $11.7K |
| Dec 1, 2025 | Balu Ganesh Ayyar
Officer
|
Grant | 902 | - |
| Dec 1, 2025 | Jatin Pravinchandra Dalal
Chief Financial Officer
|
Grant | 2.0K | - |
| Dec 1, 2025 | Kathryn Diaz
Officer
|
Grant | 743 | - |
| Dec 1, 2025 | Surya Kumari Gummadi
Officer
|
Grant | 1.8K | - |
| Dec 1, 2025 | Alina Kerdman
Officer
|
Grant | 225 | - |
| Dec 1, 2025 | John Sunshin Kim
Officer
|
Grant | 2.2K | - |
| Dec 1, 2025 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 5.3K | - |
| Nov 26, 2025 | Surya Kumari Gummadi
Officer
|
Sell | 7.0K | $539.6K |
| Nov 18, 2025 | Alina Kerdman
Officer
|
Sell | 160 | $11.4K |
| Nov 14, 2025 | Balu Ganesh Ayyar
Officer
|
Grant | 1.1K | - |
| Nov 14, 2025 | Kathryn Diaz
Officer
|
Grant | 377 | - |
| Nov 14, 2025 | Surya Kumari Gummadi
Officer
|
Grant | 3.5K | - |
| Nov 14, 2025 | Alina Kerdman
Officer
|
Grant | 235 | - |
| Nov 14, 2025 | John Sunshin Kim
Officer
|
Grant | 2.1K | - |
| Nov 14, 2025 | Ravi Kumar Singisetti
Chief Executive Officer
|
Grant | 5.8K | - |
| Oct 29, 2025 | John Sunshin Kim
Officer
|
Sell | 2.5K | $188.0K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.